ARUP, Labceutics Partner
News May 29, 2015
According to the partners, up to 70 percent of pharma pipelines use companion or complementary diagnostics. Under the collaboration, ARUP and Labceutics will provide pharma companies services that allow them to efficiently incorporate such tests in their drug development and commercialization efforts through lab networks.
ARUP provides test development and validation services to pharmaceutical partners through a program called PharmaDx, and is working with a number of drug firms in this regard in a variety of disease areas, including oncology and infectious diseases. According to the firm, its services reach more than 20 percent of US hospital labs.
Labceutics, a division of the personalized medicine-focused consulting firm Diaceutics, provides lab implementation services to pharma. The firm will help drug companies create lab networks to perform companion and complementary tests that are important for the delivery of their drugs, and then work with labs to ensure they are performing the tests efficiently and according to quality standards.
"With our Labceutics partnership, we will be providing specific solutions for the pharmaceutical industry with novel tests that support targeted therapy launches and ongoing clinical testing," Sherrie Perkins, senior VP of R&D at ARUP, said in a statement.
Researchers Fine-Tune Computer-Assisted Drug Repositioning Process to Treat Rare DiseasesNews
Researchers at the LSU Computational Systems Biology group have developed a sophisticated and systematic way to identify existing drugs that can be repositioned to treat a rare disease or condition.READ MORE
So Hot it Hurts: Ion channel trio underlying painful heat sensation foundNews
Researchers show that acute noxious heat sensing in mice depends on a triad of transient receptor potential (TRP) ion channels: TRPM3, TRPV1, and TRPA1.READ MORE
'Body-on-a-Chip' Could Advance Drug EvaluationNews
MIT engineers have developed new technology that could be used to evaluate new drugs and detect possible side effects before the drugs are tested in humans. Using a microfluidic platform that connects engineered tissues from up to 10 organs, the researchers can accurately replicate human organ interactions for weeks at a time.READ MORE